🔥 Friday 30 May 2025 Fri, 30 May 2025

Nova Minerals is launching a major 15,000-metre drilling campaign at its Estelle Project in Alaska, targeting gold and antimony resources to advance feasibility and permitting. The program includes maiden resource drilling at the high-grade Stibium prospect and potential expansion pending U.S. defense funding.

Nanoveu’s subsidiary EMASS has hit a key milestone with its ECS-DoT chip achieving 50 updates per second in drone flight simulations, enabling smarter, more stable drones with up to 30% longer flight times.

RareX Limited has partnered with Gega Elements to develop Australia’s inaugural integrated gallium supply chain, aiming to reduce reliance on Chinese supply and boost national critical mineral resilience.

The Arkansas Oil & Gas Commission has approved a 2.5% lithium royalty for brine projects, providing Pantera Lithium with regulatory clarity and a competitive fiscal framework that enhances its Smackover Project’s commercial prospects.

White Cliff Minerals reports compelling new assay results from its Rae Copper Project in Nunavut, revealing extensive high-grade copper and silver mineralisation along a 5km strike. The findings set the stage for expanded drilling and geophysical surveys to unlock the project's full potential.

Meeka Metals is on track to commission its upgraded processing plant at the Murchison Gold Project by June 2025, aiming for first gold production shortly thereafter. The company has also expanded its workforce accommodations and advanced underground mine preparations.

Lunnon Metals has revealed promising results from sterilisation drilling near its Lady Herial gold deposit, uncovering a new stacked gold structure that could expand resource potential.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.